中危脑膜瘤:NRG Oncology RTOG 0539 的初步结局
NRG Oncology RTOG 0539 是一项 II 期临床试验,将脑膜瘤患者按 WHO 级别、复发状态和切除程度分为 3 个预后组。中危组患者接受放疗 54 Gy/30 次,3 年无进展生存率为 93.8%(p = 0.0003),3 年局部失败率为 4.1%,3 年总生存率为 96%,不良事件限于 1–2 级。
要点
- 中危组 3 年无进展生存率为 93.8%(p = 0.0003),3 年局部失败率为 4.1%,3 年总生存率为 96%。
- 52 例可评估患者中 44 例(84.6%)接受调强放疗,不良事件限于 1–2 级,无 3 级事件报告。
- 新诊断 WHO II 级全切除与复发 WHO I 级两组间无进展生存无显著差异(p = 0.52,HR 0.56,95% CI 0.09-3.35)。
核心结论
- 中危脑膜瘤患者接受放疗后 3 年无进展生存率优良,局部失败率低,不良事件风险低。
- 作者认为这些结果支持对新诊断全切除的 WHO II 级或复发 WHO I 级脑膜瘤(不论切除范围)行术后放疗。
- 作者报告调强放疗毒性极小且肿瘤控制率高。
研究设计与样本
- NRG Oncology RTOG 0539 是一项 II 期临床试验,按 WHO 级别、复发状态和切除程度将脑膜瘤患者分配至 3 个预后组及相应管理策略。
- 中危组(第 2 组)入组条件为新诊断 WHO II 级脑膜瘤已行肉眼全切除(Simpson I–III 级),或复发 WHO I 级脑膜瘤不论切除范围。
- 病理和影像均行中心复核。
- 放疗采用调强放疗(IMRT)或三维适形放疗(3DCRT),54 Gy 分 30 次;靶区为瘤床及任何结节样强化,边距最小 8 mm、最大 15 mm,取决于肿瘤位置和放疗方法的摆位重复性。
- 中危组共入组 56 例,其中 3 例不合格、1 例未接受放疗;52 例接受方案治疗,4 例在 3 年前无复发性退出,48 例可评估主要终点。
主要发现
- 3 年无进展生存率经寿命表法计算为 93.8%(p = 0.0003)。
- 3 年内 3 例患者发生影响无进展生存的事件:1 例 WHO II 级患者死于疾病,1 例 WHO II 级患者疾病进展但仍存活,1 例复发 WHO I 级患者死于未明原因且无肿瘤进展。
- 3 年局部失败率为 4.1%,3 年总生存率为 96%。
- 3 年后另有 2 例患者出现进展:1 例复发 WHO I 级和 1 例 WHO II 级,两者均存活。
- 52 例可评估患者中 36 例(69.2%)为 WHO II 级肿瘤并接受肉眼全切除,16 例(30.8%)为复发 WHO I 级肿瘤;两亚组间无进展生存无显著差异(p = 0.52,HR 0.56,95% CI 0.09-3.35)。
关键数值与推荐
- 主要终点 3 年无进展生存率的预设历史对照为:单纯肉眼全切除后 3 年无进展生存率 70%,肉眼全切除+放疗后 90%。
- 放疗剂量为 54 Gy 分 30 次,靶区边距最小 8 mm、最大 15 mm。
- 不良事件采用 NCI 常见毒性标准评分,与方案治疗肯定、很可能或可能相关的不良事件限于 1 级或 2 级,无 3 级事件报告。
- 52 例可评估患者中 44 例(84.6%)接受 IMRT,50 例(96.2%)按方案或可接受变异治疗。
临床怎么用
- 作者认为这些结果支持对新诊断肉眼全切除的 WHO II 级或复发 WHO I 级脑膜瘤(不论切除范围)行术后放疗。
- 作者报告 IMRT 毒性极小且肿瘤控制率高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE This is the first clinical outcomes report of NRG Oncology RTOG 0539, detailing the primary endpoint, 3-year progression-free survival (PFS), compared with a predefined historical control for intermediate-risk meningioma, and secondarily evaluating overall survival (OS), local failure, and prospectively scored adverse events (AEs). METHODS NRG Oncology RTOG 0539 was a Phase II clinical trial allocating meningioma patients to 1 of 3 prognostic groups and management strategies according to WHO grade, recurrence status, and resection extent. For the intermediate-risk group (Group 2), eligible patients had either newly diagnosed WHO Grade II meningioma that had been treated with gross-total resection (GTR; Simpson Grades I-III) or recurrent WHO Grade I meningioma with any resection extent. Pathology and imaging were centrally reviewed. Patients were treated with radiation therapy (RT), either intensity modulated (IMRT) or 3D conformal (3DCRT), 54 Gy in 30 fractions. The RT target volume was defined as the tumor bed and any nodular enhancement (e.g., in patients with recurrent WHO Grade I tumors) with a minimum 8-mm and maximum 15-mm margin, depending on tumor location and setup reproducibility of the RT method. The primary endpoint was 3-year PFS. Results were compared with historical controls (3-year PFS: 70% following GTR alone and 90% with GTR + RT). AEs were scored using NCI Common Toxicity Criteria. RESULTS Fifty-six patients enrolled in the intermediate-risk group, of whom 3 were ineligible and 1 did not receive RT. Of the 52 patients who received protocol therapy, 4 withdrew without a recurrence before 3 years leaving 48 patients evaluable for the primary endpoint, 3-year PFS, which was actuarially 93.8% (p = 0.0003). Within 3 years, 3 patients experienced events affecting PFS: 1 patient with a WHO Grade II tumor died of the disease, 1 patient with a WHO Grade II tumor had disease progression but remained alive, and 1 patient with recurrent WHO Grade I meningioma died of undetermined cause without tumor progression. The 3-year actuarial local failure rate was 4.1%, and the 3-year OS rate was 96%. After 3 years, progression occurred in 2 additional patients: 1 patient with recurrent WHO Grade I meningioma and 1 patient with WHO Grade II disease; both remain alive. Among 52 evaluable patients who received protocol treatment, 36 (69.2%) had WHO Grade II tumors and underwent GTR, and 16 (30.8%) had recurrent WHO Grade I tumors. There was no significant difference in PFS between these subgroups (p = 0.52, HR 0.56, 95% CI 0.09-3.35), validating their consolidation. Of the 52 evaluable patients, 44 (84.6%) received IMRT, and 50 (96.2%) were treated per protocol or with acceptable variation. AEs (definitely, probably, or possibly related to protocol treatment) were limited to Grade 1 or 2, with no reported Grade 3 events. CONCLUSIONS This is the first clinical outcomes report from NRG Oncology RTOG 0539. Patients with intermediate-risk meningioma treated with RT had excellent 3-year PFS, with a low rate of local failure and a low risk of AEs. These results support the use of postoperative RT for newly diagnosed gross-totally resected WHO Grade II or recurrent WHO Grade I meningioma irrespective of resection extent. They also document minimal toxicity and high rates of tumor control with IMRT. Clinical trial registration no.: NCT00895622 (clinicaltrials.gov).
引用
- Rogers L, Zhang P, Vogelbaum MA, et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2017. PMID: 28984517. doi:10.3171/2016.11.JNS161170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。